TMO Quantitative Stock Analysis

Validea's guru fundamental report indicates that Thermo Fisher Scientific (TMO) is a large-cap growth stock with a 66% rating based on their P/B Growth Investor model, inspired by Partha Mohanram's strategy, which favors low book-to-market stocks exhibiting sustained growth characteristics. While TMO passes criteria related to book/market ratio, return on assets, cash flow, and sales variance, it fails in areas of advertising, capital expenditures, and research and development relative to assets, suggesting mixed signals for investors following this particular growth strategy.

Analysis

Thermo Fisher Scientific (TMO), a large-cap growth stock in the Medical Equipment & Supplies industry, received a 66% rating from Validea's P/B Growth Investor model, which is based on Partha Mohanram's strategy targeting low book-to-market stocks with sustained future growth characteristics. This score is below the 80% threshold typically indicating strategy interest, reflecting a neutral overall assessment as also suggested by a general sentiment score of -0.05 and a per-ticker sentiment of 0.0 for TMO. TMO successfully met criteria related to its book/market ratio, return on assets, cash flow from operations to assets, the relationship between cash flow and return on assets, return on assets variance, and sales variance, indicating solid performance in these fundamental aspects. However, the company failed tests concerning advertising to assets, capital expenditures to assets, and research and development to assets. These failures, according to Mohanram's specific criteria, could suggest potential underinvestment in key growth-driving areas, presenting a mixed profile for TMO despite its strengths in operational efficiency and financial stability highlighted by the passed metrics.

Key Decisions for Investors

• Investors strictly adhering to Partha Mohanram's P/B Growth Investor model should note TMO's 66% rating, which is below the model's typical interest threshold, primarily due to its failure to meet criteria for advertising, capital expenditure, and R&D relative to assets.
• Consider investigating TMO's capital allocation strategy, particularly its expenditure on advertising, capex, and R&D, to understand if these levels support its long-term growth ambitions within the Medical Equipment & Supplies sector, even if they don't align with this specific model's ideal.
• While TMO exhibits strengths in several fundamental areas like return on assets and cash flow generation, the model's overall assessment warrants caution for those relying heavily on Mohanram's specific growth indicators, suggesting a need for broader due diligence or consideration of TMO within alternative investment frameworks.